e-learning
resources
London 2016
Tuesday, 06.09.2016
Novel avenues in the treatment of COPD II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment
Iryna Savelikhina (Ivano-Frankivsk, Ukraine), Iryna Savelikhina, Oleksandr Varunkiv, Mykola Ostrovskyy, Mariana Kulynych-Miskiv, Kseniia Ostrovska
Source:
International Congress 2016 – Novel avenues in the treatment of COPD II
Session:
Novel avenues in the treatment of COPD II
Session type:
Thematic Poster
Number:
4072
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Iryna Savelikhina (Ivano-Frankivsk, Ukraine), Iryna Savelikhina, Oleksandr Varunkiv, Mykola Ostrovskyy, Mariana Kulynych-Miskiv, Kseniia Ostrovska. The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment. Eur Respir J 2016; 48: Suppl. 60, 4072
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Macrolide effects on the prevention of COPD exacerbations
Source: Eur Respir J 2012; 40: 485-494
Year: 2012
Effects of dexamethasone and anti-inflammatory drugs on inflammatory cytokines from bronchial epithelial cells of COPD patients
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
New anti-inflammatory activities of Alpha-1-Antitrypsin and their role in COPD
Source: Annual Congress 2005 - Protease-antiprotease revisited
Year: 2005
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma
Source: Annual Congress 2005 - Mechanisms of resolution of inflammation
Year: 2005
TNFalpha release by monocyte-derived macrophages at stable and exacerbation states in COPD
Source: International Congress 2014 – COPD physiopathology
Year: 2014
Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
COPD, an inflammatory systemic disease. Inflammatory parameters in a group of COPD patients
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
MIG and IP-10 levels in induced sputum of stable and exacerbated COPD patients
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
Changes of TNF-a level in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease before and after the 30 days treatment with tiotropium bromide
Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects
Year: 2015
Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
IL-17A is specifically elevated in NTHi-associated AECOPD and end-stage COPD
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Pathology, inflammation and cytokines of severe asthma
Source: Eur Respir Mon 2011; 51: 97-106
Year: 2011
PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept